Search

Editas Medicine Inc

Suletud

SektorTervishoid

3.06 -1.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.98

Max

3.15

Põhinäitajad

By Trading Economics

Sissetulek

6.8M

-18M

Müük

9.1M

12M

Aktsiakasum

-0.15

Kasumimarginaal

-153.322

Töötajad

87

EBITDA

3.9M

-20M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+87.91% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

9. nov 2026

Turustatistika

By TradingEconomics

Turukapital

63M

470M

Eelmine avamishind

4.67

Eelmine sulgemishind

3.06

Uudiste sentiment

By Acuity

63%

37%

285 / 340 Pingereas Healthcare

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. sept 2026, 19:16 UTC

News

Editas Medicine is participating in two investor conferences, enhancing visibility. Shares are higher today, reflecting positive investor interest in its CRISPR technology focus.

31. aug 2026, 22:51 UTC

News

Editas Medicine has filed a prospectus for a $400 million mixed securities shelf offering, contributing to higher shares during after-market hours.

28. aug 2026, 20:03 UTC

Editas Medicine Inc shares are lower today, retracing from earlier highs. Broader market dynamics, including rising Treasury yields, may be contributing to the decline.

27. aug 2026, 23:02 UTC

Editas Medicine Inc is trading higher in after-market hours, reflecting positive sentiment since Thursday's close and resilience despite earlier session pullbacks.

26. aug 2026, 23:16 UTC

Editas Medicine Inc shares are higher in after-market trading, positioned near the upper end of their one-month range and above the 20-day moving average.

25. aug 2026, 19:21 UTC

Correlated Moves

Editas Medicine Inc is seeing gains during Tuesday's session, reaching a peak return earlier before pulling back slightly. Broader market sentiment remains favorable for biotech stocks.

24. aug 2026, 22:22 UTC

Editas Medicine Inc shares are higher in after-market trading, showing some volatility. No specific news was identified to explain the price movement.

21. aug 2026, 23:16 UTC

Editas Medicine Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock remains above its 20-day moving average.

20. aug 2026, 23:46 UTC

Editas Medicine Inc is higher in after-market hours, gaining since Thursday's close. The stock is above its 20-day moving average amid no specific news.

19. aug 2026, 23:21 UTC

Editas Medicine Inc. shares are lower in after-market hours, impacted by a decline in the Biotechnology sub-sector. No specific news was identified for the movement.

17. aug 2026, 19:16 UTC

Editas Medicine Inc. shares are trading roughly flat amid overall market sentiment influenced by recent declines in U.S. retail sales and consumer sentiment.

14. aug 2026, 22:21 UTC

Editas Medicine Inc is trading lower in after-market hours, continuing a decline over the past four sessions amid broader concerns over consumer demand.

13. aug 2026, 21:32 UTC

Correlated Moves

Editas Medicine Inc advanced in after-hours trading, reflecting a shift in investor sentiment and aligning with a positive trend in the biotechnology sector.

12. aug 2026, 19:31 UTC

Editas Medicine Inc shares are lower today, continuing a decline since Tuesday. No specific news has been identified to explain the drop.

11. aug 2026, 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

10. aug 2026, 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

7. aug 2026, 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

6. aug 2026, 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

5. aug 2026, 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

31. juuli 2026, 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

30. juuli 2026, 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

29. juuli 2026, 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

28. juuli 2026, 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

27. juuli 2026, 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

24. juuli 2026, 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

22. juuli 2026, 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

21. juuli 2026, 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

87.91% tõus

12 kuu keskmine prognoos

Keskmine 5.75 USD  87.91%

Kõrge 8 USD

Madal 4 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

1

Hoia

1

Müü

Sentiment

By Acuity

285 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat